• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

Risk Factors for Type 1 Diabetes: A Snapshot for Primary Care

Commentary
Slideshow

About 40% of people who have T1D are not aware of it until they experience an extreme health event; screening in primary care can help reduce the risk, support families.

slideshow image

Routine screening for type 1 diabetes in the general population is not currently recommended due to its relatively low prevalence. However, screening is strongly advised for high-risk populations—those with a family history of T1D or certain genetic markers associated with increased risk.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Impact of Social Determinants of Health on Key Cardiometabolic Measures Amplified by New Research
Intermediate Cardiometabolic Risk: Study Author Explains this "Critical Inflection Point"
Intermediate Cardiometabolic Risk: Study Author Explains this "Critical Inflection Point"
US Cardiometabolic Health at Alarming Suboptimal Levels, Says Lead Author of New NHANES Analysis
US Cardiometabolic Health at Alarming Suboptimal Levels, Says Lead Author of New NHANES Analysis
Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools
Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools
Lessons Learned from the VA on Delay in Second-line Treatment for Type 2 Diabetes
Lessons Learned from the VA on Delay in Second-line Treatment for Type 2 Diabetes
VA Clinical Investigator Discusses HbA1c, Comorbidities as Markers for T2D Treatment Intensification
VA Clinical Investigator Discusses HbA1c, Comorbidities as Markers for T2D Treatment Intensification
DiabetesWise Pro: Side-by-side, Feature-by-feature CGM Comparison, Plus More
DiabetesWise Pro: Side-by-side, Feature-by-feature CGM Comparison, Plus More
A Guide to Prescribing the Right Diabetes Device for your Patients, with DiabetesWise Pro Developer Korey Hood, PhD
A Guide to Prescribing the Right Diabetes Device for your Patients, with DiabetesWise Pro Developer Korey Hood, PhD
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
Related Content
New Guidelines Recommend Preconception Screening in Diabetes: Daily Dose / image credit: ©New Africa/AdobeStock

New Guidelines Recommend Preconception Screening in Diabetes: Daily Dose

Sydney Jennings
August 4th 2025
Article

Your daily dose of the clinical news you may have missed.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

GLP-1 RAs vs Metformin Significantly Reduce Risk of Dementia in Adults with Type 2 Diabetes / image credit ©Visualmind/stock.adobe.com

GLP-1 RAs vs Metformin Significantly Reduce Risk of Dementia in Adults with Type 2 Diabetes

Grace Halsey
July 24th 2025
Article

Both metformin and GLP-1 RAs have been studies for their neuroprotective effects; this study is the first head-to-head investigation and supports further research.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings
July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

What is Driving Type 2 Diabetes in the US? / image credit ©Zsido/Shutterstock.com

What is Driving Type 2 Diabetes in the US?

Grace Halsey
July 22nd 2025
Article

Type 2 diabetes and its high and rising rates in the US are the result of a perfect storm of converging systemic, behavioral, environmental, and economic factors.

Weight Loss Achievable Despite Interruptions in GLP-1 Medication Access, Study Finds

Weight Loss Achievable Despite Interruptions in GLP-1 Medication Access, Study Finds

Sydney Jennings
July 16th 2025
Article

ENDO 2025. People with inconsistent access to GLP-1 medications still achieved clinically significant weight loss when therapy was combined with lifestyle changes and coaching.

© 2025 MJH Life Sciences

All rights reserved.